日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer

在激素受体阳性/HER2阴性转移性乳腺癌的治疗过程中，制定个性化治疗方案

期刊:Ca-A Cancer Journal for Clinicians
影响因子:232.4
doi:10.3322/caac.70055
Singareeka Raghavendra, Akshara; Damodaran, Senthil; Barcenas, Carlos H; Fuqua, Suzanne A; Layman, Rachel M; Tripathy, Debu
肿瘤
HER2
肿瘤免疫
信号转导
乳腺癌
免疫/内分泌
发表日期：2026
文献求助 收藏

Prevalence of HER2-low status and outcomes in early-stage HER2-negative breast cancer

HER2低表达状态的患病率及早期HER2阴性乳腺癌的预后

期刊:NPJ Breast Cancer
影响因子:7.6
doi:10.1038/s41523-026-00901-8
Singareeka Raghavendra, Akshara; Liu, Diane D; Pasyar, Sarah; Damodaran, Senthil; Shen, Yu; Mouabbi, Jason A; Barcenas, Carlos H; Tripathy, Debu
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Prevalence and Outcomes of HER2-Low Versus HER2-0 Status in Patients with Metastatic Breast Cancer

转移性乳腺癌患者中 HER2 低表达与 HER2 零表达状态的患病率和预后

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers18020253
Singareeka Raghavendra, Akshara; Liu, Diane D; Damodaran, Senthil; Pasyar, Sarah; Shen, Yu; Mouabbi, Jason A; Barcenas, Carlos H; Hunt, Kelly K; Tripathy, Debu
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2- metastatic breast cancer.

单细胞 RNA 测序可识别预测 HR+/HER2-转移性乳腺癌患者 CDK4/6 抑制剂治疗后期进展的分子生物标志物

期刊:Molecular Cancer
影响因子:33.9
doi:10.1186/s12943-025-02226-9
Luo Linjie, Yang Peng, Mastoraki Sofia, Rao Xiayu, Wang Yan, Kettner Nicole M, Raghavendra Akshara Singareeka, Tripathy Debasish, Damodaran Senthil, Hunt Kelly K, Wang Jing, Li Ziyi, Keyomarsi Khandan
细胞生物学
乳腺癌
发表日期：2025
文献求助 收藏

Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors.

帕博利珠单抗联合瘤内注射诺维梭菌-NT治疗晚期实体瘤患者的Ib期研究。

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-3952
Nelson Blessie Elizabeth, Janku Filip, Fu Siqing, Dumbrava Ecaterina E, Hong David S, Karp Daniel D, Naing Aung, Rodon Jordi, Tsimberidou Apostolia M, Murthy Ravi, Sheth Rahul A, Amaria Rodabe N, Conley Anthony P, Damodaran Senthil, Raghav Kanwal P S, Carapanceanu Nicoleta, Singh Mahendra Pal, Carapanceanu Valentin, Pezeshki Abdulmohammad, Leontovich Alexey A, Kreider Brent L, Tung David, Varterasian Mary, Khazaie Khashayarsha, Piha-Paul Sarina A
肿瘤
发表日期：2025
文献求助 收藏

Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models.

TROP2 抗体-药物偶联物 Datopotamab Deruxtecan 在患者来源的乳腺癌异种移植模型中的抗肿瘤活性和生物标志物分析

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-1948
Meric-Bernstam Funda, Yuca Erkan, Evans Kurt W, Zhao Ming, Maejima Takanori, Karibe Tsuyoshi, Raso Maria Gabriela, Tang Ximing, Zheng Xiaofeng, Rizvi Yasmeen Qamar, Akcakanat Argun, Scott Stephen M, Wang Bailiang, Byers Lauren A, Tripathy Debu, Okajima Daisuke, Damodaran Senthil
肿瘤
乳腺癌
发表日期：2025
文献求助 收藏

Clinical Characteristics and Survival Outcomes of Metastatic Invasive Lobular and Ductal Carcinoma

转移性浸润性小叶癌和导管癌的临床特征和生存结局

期刊:Jama Network Open
影响因子:9.7
doi:10.1001/jamanetworkopen.2025.1888
Raghavendra, Akshara S; Bassett, Roland Jr; Damodaran, Senthil; Barcenas, Carlos H; Mouabbi, Jason A; Layman, Rachel; Tripathy, Debu
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer.

IL-6 预测 CDK4/6 抑制剂耐药性，确定 STAT3 为 HR+/HER2 阴性转移性乳腺癌的靶点

期刊:npj Precision Oncology
影响因子:8
doi:10.1038/s41698-025-01041-1
Kettner Nicole M, Bui Tuyen N, Navarro-Yepes Juliana, Ghotbaldini Sanaz, Quintela Bethanie, Luo Catherine K, Lam Nghi, Rao Xiayu, Raghavendra Akshara Singareeka, Wang Yan, Azizian Nancy, Kris Eckols T, Kasembeli Moses Makokha, Evans Kurt, Yi Min, Wingate Hannah, Wang Jing, Sahin Aysegul A, Meric-Bernstam Funda, Hunt Kelly K, Damodaran Senthil, Tweardy David J, Tripathy Debu, Keyomarsi Khandan
肿瘤
乳腺癌
IL-6
STAT3
发表日期：2025
文献求助 收藏

ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1-mutated, metastatic breast cancer

ELAINE 3：拉索昔芬联合阿贝西利治疗ER+/HER2-、ESR1突变转移性乳腺癌的3期研究

期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2025.2481825
Goetz, Matthew P; Wander, Seth A; Bachelot, Thomas; de Nonneville, Alexandre; Gal-Yam, Einav Nili; Sammons, Sarah L; Shen, Sherry; Twelves, Chris; Boruta, Gina; Portman, David J; Damodaran, Senthil
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Durable disease regression with copanlisib treatment in PI3K-mutated metastasizing ameloblastoma: A case report

copanlisib治疗PI3K突变转移性成釉细胞瘤可实现持久的疾病缓解：病例报告

期刊:Rare Tumors
影响因子:0.9
doi:10.1177/20363613241309961
Lynch, Meghan M; Hermida-Viveiros, Pedro; Stencel, Sean; Knott, Hannah; Al-Maryati, Rusul; Obeidin, Farres; Alexiev, Borislav A; Abbinanti, Susan; Damodaran, Senthil; Agulnik, Mark; Pollack, Seth M
细胞生物学
发表日期：2025
文献求助 收藏